Aprea Therapeutics Inc (APRE)vsInsmed Inc (INSM)
APRE
Aprea Therapeutics Inc
$0.67
-0.39%
HEALTHCARE · Cap: $8.73M
INSM
Insmed Inc
$148.31
+6.59%
HEALTHCARE · Cap: $29.99B
Smart Verdict
WallStSmart Research — data-driven comparison
Insmed Inc generates 124106% more annual revenue ($606.42M vs $488,240). APRE leads profitability with a 0.0% profit margin vs -2.1%. INSM earns a higher WallStSmart Score of 39/100 (F).
APRE
Avoid23
out of 100
Grade: F
INSM
Hold39
out of 100
Grade: F
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Reasonable price relative to book value
No standout strengths identified
Areas to Watch
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
ROE of -74.7% — below average capital efficiency
1.5% revenue growth
0.0% earnings growth
Trading at 43.0x book value
ROE of -2.5% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : APRE
The strongest argument for APRE centers on Price/Book.
Bull Case : INSM
PEG of 1.09 suggests the stock is reasonably priced for its growth.
Bear Case : APRE
The primary concerns for APRE are EPS Growth, Market Cap, Profit Margin.
Bear Case : INSM
The primary concerns for INSM are Revenue Growth, EPS Growth, Price/Book.
Key Dynamics to Monitor
APRE profiles as a value stock while INSM is a turnaround play — different risk/reward profiles.
APRE carries more volatility with a beta of 1.55 — expect wider price swings.
INSM is growing revenue faster at 1.5% — sustainability is the question.
APRE generates stronger free cash flow (-3M), providing more financial flexibility.
Bottom Line
INSM scores higher overall (39/100 vs 23/100). Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Aprea Therapeutics Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and markets cancer therapies that reactivate the mutant p53 tumor suppressor protein. The company is headquartered in Boston, Massachusetts.
Insmed Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Insmed Incorporated, a biopharmaceutical company, develops and markets therapies for patients with rare and serious diseases. The company is headquartered in Bridgewater, New Jersey.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?